NP方案与TP方案对初治晚期非小细胞肺癌疗效的对比观察  

Clinical observation on original chemotherapy for advanced non-small cell lung cancer between NP and TP

作　　者：周超[1] 胡斌[1] 彭卫东[1] 方平[1] 

机构地区：[1]铜陵市人民医院呼吸内科

出　　处：《临床肿瘤学杂志》2006年第10期749-751,共3页Chinese Clinical Oncology

摘　　要：目的:探讨NP方案和TP方案对初治晚期非小细胞肺癌(NSCLC)的疗效和毒性。方法:63例晚期NSCLC患者(Ⅲ期39例占61·9%,Ⅳ期24例占38·1%)按所接受的化疗方案分成NP组和TP组,每例患者至少接受2个周期以上的同一方案治疗,比较两组方案治疗的效果和不良反应。结果:NP组和TP组的总有效率分别为42·9%、46·4%;1年生存率分别为22·9%、25·0%;2年生存率分别为8·6%、7·1%;NP组和TP组患者的中位生存期分别为8·5个月和8·7个月,两组间比较无统计学意义(P>0·05)。NP组和TP组的不良反应均在可耐受范围。结论:NP方案和TP方案对晚期NSCLC的疗效确切,可作为晚期初治NSCLC的一线化疗方案。Objective： To evaluate the efficacy of the NP/TP regimen on advanced non-small cell lung cancer（NSCLC）. Methods ：63 patients with advanced NSCLC were retrospectively analyzed. All the patients were divided into two groups,in all cases,39 patients（61.9% ） were in stage Ⅲ,24 patients（38. 1% ） were in stage Ⅳ ,all the patients had accepted intravenous chemotherapy and preponderated over 2 cycles. And a clinical control observation on effectiveness and adverse effects was carried out in two groups. Re- sults：The total effective rate for advanced NSCLC in NP group and TP group were 42.9% （ 15/35 ） and 46. 4% （13/28） ,respectively; The median survival time were 8.5 months and 8.7 months, respectively. 1-year survival rates were 22. 9% and 25, 0% ,respectively. 2- year survival rates were 8.6% and 7. 1% ,respectively, The survival state and the short term effectiveness in two groups had no statistically significant difference （ P〉0.05 ）. In the adverse effects of treatment, the main toxicity included the gastrointestinal disturbance and bone marrow suppression,but they were tolerable. Conclusion： NP/TP regimen on advanced NSCLC shows more effectiveness and tolerance,they could become the original chemotherapy in advenced NSCLC.

关 键 词：非小细胞肺癌 化疗 NP方案 TP方案 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]